• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 285

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

Experts Predict What 2021 Psychedelics Space Might Look Like

New Hawaii Senate Bill May See Psilocybin Mushroom Therapy Legalized

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Updates...

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One...

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

Somerville, Massachusetts, Passes Measure to Decriminalize Psychedelics

You Don’t Have to Take Psychedelics to Benefit from Them —...

PTSF 44 (with Colin Thompson, director of “Light Years”)

PT228 – Deborah Snyder from Synergetic Press

PTSF 43

1...284285286...292Page 285 of 292

EDITOR PICKS

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©